Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Snowdrifton Mar 18, 2024 9:19am
172 Views
Post# 35937977

RE:Yet another new week…

RE:Yet another new week…Sorry for your loss, Canadafan.

canadafan wrote: Oncolytics biotech has been though multiple weeks of relative silence.
The Q4 update was focused mostly on expanding production.
Thst imho is a huge signal of an expected positive future.
Not sure why thst is getting next to zero focus.
For those who are sharholders. I wish everyone a prosperous few weeks.
With funding into 2025, it is quite possible for mangement to move forward & await for the bracelet trial overall survival numbers.
An Intersting paradox!
The O.S. Numbers are based on survival of the patients.
obviously a number of which have not passed away yet.
That is great news for them & the trial.
Yet withiut the events ,the stats can not be indentified.
I would think that once certian timelines have beensurpassed. That general " event" can be discussed.
Something, I can look into.
anyine know of such dates?
again a paradox. The longer things wait, the closer to registration & the more valuable.
Yet, seeing " no activity" the SP drops.
A lot o& people will be saying " would, have , could have should have"
great Week all 
stay safe & stay healthy.
i lost another friend to Cancer last week.






<< Previous
Bullboard Posts
Next >>